GENFIT (GNFT.PA) Stock Fundamental Analysis
EPA:GNFT - Euronext Paris - Matif - FR0004163111 - Common Stock - Currency: EUR
GNFT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 72 industry peers in the Biotechnology industry. Both the profitability and the financial health of GNFT get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, GNFT is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year GNFT was profitable.
In the past year GNFT had a positive cash flow from operations.
In multiple years GNFT reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: GNFT reported negative operating cash flow in multiple years.
1.2 Ratios
GNFT's Return On Assets of 1.00% is fine compared to the rest of the industry. GNFT outperforms 70.83% of its industry peers.
GNFT has a Return On Equity of 2.18%. This is in the better half of the industry: GNFT outperforms 73.61% of its industry peers.
GNFT has a better Return On Invested Capital (3.45%) than 80.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1% | ||
| ROE | 2.18% | ||
| ROIC | 3.45% |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 2.12%, GNFT is doing good in the industry, outperforming 73.61% of the companies in the same industry.
GNFT's Profit Margin has declined in the last couple of years.
GNFT's Operating Margin of 4.55% is fine compared to the rest of the industry. GNFT outperforms 79.17% of its industry peers.
GNFT's Operating Margin has declined in the last couple of years.
GNFT has a Gross Margin of 97.11%. This is amongst the best in the industry. GNFT outperforms 95.83% of its industry peers.
In the last couple of years the Gross Margin of GNFT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.55% | ||
| PM (TTM) | 2.12% | ||
| GM | 97.11% |
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GNFT is destroying value.
The number of shares outstanding for GNFT has been increased compared to 1 year ago.
Compared to 5 years ago, GNFT has more shares outstanding
The debt/assets ratio for GNFT is higher compared to a year ago.
2.2 Solvency
GNFT has an Altman-Z score of -1.71. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
GNFT has a Altman-Z score (-1.71) which is in line with its industry peers.
GNFT has a debt to FCF ratio of 4.26. This is a neutral value as GNFT would need 4.26 years to pay back of all of its debts.
GNFT has a better Debt to FCF ratio (4.26) than 84.72% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that GNFT is not too dependend on debt financing.
GNFT has a better Debt to Equity ratio (0.08) than 69.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 4.26 | ||
| Altman-Z | -1.71 |
ROIC/WACC0.48
WACC7.21%
2.3 Liquidity
A Current Ratio of 1.23 indicates that GNFT should not have too much problems paying its short term obligations.
GNFT has a Current ratio of 1.23. This is in the lower half of the industry: GNFT underperforms 68.06% of its industry peers.
GNFT has a Quick Ratio of 1.23. This is a normal value and indicates that GNFT is financially healthy and should not expect problems in meeting its short term obligations.
GNFT has a Quick ratio of 1.23. This is in the lower half of the industry: GNFT underperforms 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.23 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 105.17% over the past year.
The earnings per share for GNFT have been decreasing by -70.77% on average. This is quite bad
The Revenue has grown by 85.82% in the past year. This is a very strong growth!
Measured over the past years, GNFT shows a quite strong growth in Revenue. The Revenue has been growing by 11.61% on average per year.
EPS 1Y (TTM)105.17%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-212.5%
Revenue 1Y (TTM)85.82%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-53%
3.2 Future
GNFT is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -45.31% yearly.
Based on estimates for the next years, GNFT will show a decrease in Revenue. The Revenue will decrease by -1.64% on average per year.
EPS Next Y-118.61%
EPS Next 2Y-45.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.14%
Revenue Next 2Y-20.11%
Revenue Next 3Y10.24%
Revenue Next 5Y-1.64%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 110.13 indicates a quite expensive valuation of GNFT.
GNFT's Price/Earnings ratio is a bit cheaper when compared to the industry. GNFT is cheaper than 76.39% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.92. GNFT is valued rather expensively when compared to this.
GNFT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 110.13 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, GNFT is valued a bit cheaper than 73.61% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of GNFT indicates a rather cheap valuation: GNFT is cheaper than 91.67% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.31 | ||
| EV/EBITDA | 29.78 |
4.3 Compensation for Growth
GNFT's earnings are expected to decrease with -45.31% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-45.31%
EPS Next 3YN/A
5. Dividend
5.1 Amount
GNFT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:GNFT (6/27/2025, 7:00:00 PM)
3.304
-0.05 (-1.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap164.74M
Analysts90.77
Price Target9.66 (192.37%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.07%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)84.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)117.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 110.13 | ||
| Fwd PE | N/A | ||
| P/S | 2.32 | ||
| P/FCF | 11.31 | ||
| P/OCF | 10.59 | ||
| P/B | 2.38 | ||
| P/tB | 7.76 | ||
| EV/EBITDA | 29.78 |
EPS(TTM)0.03
EY0.91%
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)0.29
FCFY8.84%
OCF(TTM)0.31
OCFY9.44%
SpS1.42
BVpS1.39
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1% | ||
| ROE | 2.18% | ||
| ROCE | 4.23% | ||
| ROIC | 3.45% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 4.55% | ||
| PM (TTM) | 2.12% | ||
| GM | 97.11% | ||
| FCFM | 20.54% |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 4.26 | ||
| Debt/EBITDA | 1.12 | ||
| Cap/Depr | 56.79% | ||
| Cap/Sales | 1.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 314.19% | ||
| Profit Quality | 966.82% | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.23 | ||
| Altman-Z | -1.71 |
F-Score7
WACC7.21%
ROIC/WACC0.48
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)105.17%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-212.5%
EPS Next Y-118.61%
EPS Next 2Y-45.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)85.82%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-53%
Revenue Next Year3.14%
Revenue Next 2Y-20.11%
Revenue Next 3Y10.24%
Revenue Next 5Y-1.64%
EBIT growth 1Y112.1%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year67.69%
EBIT Next 3Y62.39%
EBIT Next 5YN/A
FCF growth 1Y125.16%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y128.05%
OCF growth 3Y-46.21%
OCF growth 5YN/A